dalteparin has been researched along with Uterine Cervical Neoplasms in 4 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.
| Excerpt | Relevance | Reference |
|---|---|---|
| "However, in breast cancer patients who received LMW heparin the impact of classical tumor prognostic markers was statistically significant after 1,050 days but not after 650 days." | 2.69 | Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. ( Harenberg, J; Heilmann, L; Hommel, G; Kirkpatrick, CJ; Niemann, F; von Tempelhoff, GF, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Derlatka, P | 1 |
| Bidzinski, M | 1 |
| Stachurska, E | 1 |
| Benke, M | 1 |
| Yu, R | 1 |
| Nansubuga, F | 1 |
| Yang, J | 1 |
| Ding, W | 1 |
| Li, K | 1 |
| Weng, D | 1 |
| Wu, P | 1 |
| Chen, G | 1 |
| Ma, D | 1 |
| Wei, J | 1 |
| Cunningham, MS | 1 |
| Gilmore, R | 1 |
| O'Donnell, D | 1 |
| O'Donnell, JS | 1 |
| von Tempelhoff, GF | 1 |
| Harenberg, J | 1 |
| Niemann, F | 1 |
| Hommel, G | 1 |
| Kirkpatrick, CJ | 1 |
| Heilmann, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer[NCT00718354] | Phase 3 | 740 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for dalteparin and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Nadroparine activated fibrinolysis and improvement of glomerular filtration rate in patients with FIGO IIB-IIIB cervical cancer treated with radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Combined Modality Therapy; Female; Fibrinolysis; Fibrinol | 2007 |
Efficiency and safety evaluation of prophylaxes for venous thrombosis after gynecological surgery.
Topics: Anticoagulants; Arginine; Endometrial Neoplasms; Female; Gynecologic Surgical Procedures; Heparin, L | 2020 |
Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial.
Topics: Adult; Aged; Breast Neoplasms; Double-Blind Method; Female; Heparin; Heparin, Low-Molecular-Weight; | 2000 |
1 other study available for dalteparin and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Management of refractory venous thrombosis associated with malignancy using a supra-therapeutic enoxaparin regimen.
Topics: Adult; Carcinoma, Squamous Cell; Enoxaparin; Female; Fibrinolytic Agents; Humans; International Norm | 2009 |